spironolactone has been researched along with Cirrhoses, Experimental Liver in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone can inhibit hepatic sinusoid angiogenesis in rats with BDL-induced hepatic fibrosis by inhibiting the expression of VEGF-A." | 1.38 | [Spironolactone inhibits hepatic sinusoid angiogenesis in rats with hepatic fibrosis]. ( Cai, S; Li, X; Li, Y; Ning, Z; Zhang, L; Zhang, W, 2012) |
| " Our aim was to study the hemodynamic effects of the early and chronic administration of PR and spironolactone (SPN), alone or in combination, in a model of hepatic fibrosis and sinusoidal portal hypertension induced in rats by bile duct ligation." | 1.30 | Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. ( Calès, P; Douay, O; Gallois, Y; Le Jeune, JJ; Maïga, MY; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Cai, S | 1 |
| Ning, Z | 1 |
| Li, Y | 1 |
| Zhang, W | 1 |
| Zhang, L | 1 |
| Fujisawa, G | 1 |
| Muto, S | 1 |
| Okada, K | 1 |
| Kusano, E | 1 |
| Ishibashi, S | 1 |
| Oberti, F | 2 |
| Rifflet, H | 2 |
| Maïga, MY | 2 |
| Pilette, C | 2 |
| Gallois, Y | 2 |
| Douay, O | 1 |
| Le Jeune, JJ | 2 |
| Saumet, JL | 2 |
| Calès, P | 2 |
| Moreau, A | 1 |
| Girault, A | 1 |
| le Bouil, A | 1 |
| Feldmann, G | 1 |
4 other studies available for spironolactone and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
[Spironolactone inhibits hepatic sinusoid angiogenesis in rats with hepatic fibrosis].
Topics: Animals; Hepatic Veins; Liver Cirrhosis, Experimental; Male; Neovascularization, Pathologic; Rats; R | 2012 |
Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats.
Topics: Actins; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Hydroxyproline; Kupffer Cells; Liver; Liver | 2006 |
Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.
Topics: Animals; Antihypertensive Agents; Cholestasis; Drug Evaluation, Preclinical; Drug Therapy, Combinati | 1997 |
Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation.
Topics: Animals; Bile Ducts; Blood Pressure; Double-Blind Method; Hemodynamics; Hypertension, Portal; Hypoli | 1997 |